Cytoplasm

Novocure Announces Last Patient Enrolled in Phase 3 Pivotal INNOVATE-3 Trial of Tumor Treating Fields in Ovarian Cancer

Retrieved on: 
Thursday, October 28, 2021
Oncology, Health, Clinical Trials, Research, Pharmaceutical, Science, Woman, Death, Stomach, Ovarian cancer, Pancreatic cancer, Chromosome, Data monitoring committee, Quality of life, Diagnosis, Recurrence, Neoplasm, LinkedIn, Prognosis, Cancer, Disease, Cell division, Fundamental, Survival, Mitosis, Physician, Twitter, Patient, Private Securities Litigation Reform Act, NASDAQ, Paclitaxel, Liver cancer, Large-cell lung carcinoma, European Network of Transmission System Operators for Electricity, U.S. Securities and Exchange Commission, Adult, Protein, Glioblastoma, Annual report, Forward-looking statement, Standard of care, Cytoplasm, DMC, COVID-19, Skin, Cell, Alternating electric field therapy, Cell death, Microtubule, Population, Toxicity, Incidence, Mesothelioma, Pharmaceutical industry, Medical imaging, Ovarian Cancer, Tumor Treating Fields, Novocure, OVARIAN CANCER, TUMOR TREATING FIELDS, NOVOCURE

Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with paclitaxel for treatment of patients with platinum-resistant ovarian cancer.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced that the final patient has been enrolled in phase 3 pivotal INNOVATE-3 trial evaluating the efficacy of Tumor Treating Fields (TTFields) together with paclitaxel for treatment of patients with platinum-resistant ovarian cancer.
  • INNOVATE-3 is a randomized, open-label study which was designed to enroll 540 adult patients with recurrent, platinum-resist ovarian cancer.
  • In the U.S., ovarian cancer ranks fifth in cancer deaths among women, with approximately 24,000 women diagnosed each year.
  • Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent

Retrieved on: 
Monday, October 25, 2021
Biotechnology, Technology, US, USPTO, Annual report, Element, WINT, Partnership, Cardiogenic shock, U.S. Securities and Exchange Commission, Patient, Private Securities Litigation Reform Act, Security (finance), FDA, Heart, Istaroxime, Acute respiratory distress syndrome, Hypertension, Patent, Respiratory distress syndrome, United States Patent and Trademark Office, Marketing, Company, Blood pressure, Cytoplasm, CEO, COVID-19, Growth, ADS, Sarcoplasmic reticulum, Form 10-K, Program, HK, Therapy, AHF, GLOBE, Treatment, Heart rate, Pharmaceutical industry

A notice of allowance is issued by the USPTO to indicate that the application has passed examination.

Key Points: 
  • A notice of allowance is issued by the USPTO to indicate that the application has passed examination.
  • The claims cover longer infusion durations of istaroxime for improved outcomes in treatment of acute heart failure.
  • Istaroxime is an investigational drug candidate being studied in acute heart failure and also in early cardiogenic shock.
  • The istaroxime patent estate is a priority for Windtree and we plan to add additional elements to it as data is obtained in our clinical studies.

Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Treatments for Early Cardiogenic Shock Patients (ECS) as Windtree Therapeutics Prepares for Clinical Results from its Istaroxime ECS Study

Retrieved on: 
Tuesday, October 12, 2021
Company, Oxygen, Brain, Technology, SCAI, Istaroxime, AHF, Risk, Therapy, Heart rate, Cardiogenic shock, Cardiopulmonary resuscitation, Heart, Form 10-K, Biotechnology, COVID-19, HK, GLOBE, Blood, Marketing, Growth, Safety, Respiratory distress syndrome, SBP, WINT, FDA, Cardiology, U.S. Securities and Exchange Commission, Disease, Prevalence, Lung cancer staging, Society, Private Securities Litigation Reform Act, ADS, Cytoplasm, Security (finance), Blood pressure, Annual report, Acute respiratory distress syndrome, Patient, Heart failure, Sarcoplasmic reticulum, .30-40 Krag, Hypertension, Pharmaceutical industry, Medical device

After two positive istaroxime phase 2 acute heart failure studies provided the rationale, Windtree began clinical development of istaroxime in the second disease state of early cardiogenic shock.

Key Points: 
  • After two positive istaroxime phase 2 acute heart failure studies provided the rationale, Windtree began clinical development of istaroxime in the second disease state of early cardiogenic shock.
  • Using cardiogenic shock patient US hospital claims and worldwide prevalence data, Windtree estimates the worldwide total market value of cardiogenic shock to be $1.25 billion.
  • 99 out of 100 cardiologists responded that there was high need for pharmacologic (drug) innovation in SCAI class B cardiogenic shock patients.
  • The istaroxime Phase 2 study in early cardiogenic shock is an international, randomized, double blind, placebo- controlled study.

Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

Retrieved on: 
Monday, October 4, 2021
Mortality, Cell death, Pancreatic cancer, Cytoplasm, Private Securities Litigation Reform Act, Overalls, Chromosome, Mesothelioma, Cell, Safety, Investment, Capecitabine, Protein, Glioblastoma, Microtubule, Degenerative disease, Health, U.S. Securities and Exchange Commission, LinkedIn, Adult, Infection, Twitter, Coronavirus, Ovarian cancer, Cell division, Survival, Incidence, EDGAR, Clinical trial, Mitosis, Annual report, NASDAQ, Cancer, Neoplasm, Toxicity, Alternating electric field therapy, Stomach, Large-cell lung carcinoma, Stomach cancer, HIV disease progression rates, Forward-looking statement, GLOBE, Oxaliplatin, Fundamental, Risk, Patient, XELOX, Liver cancer, COVID-19, Drug development, Data collection, Skin, Pharmaceutical industry, Medical imaging

SHANGHAI and St. Helier, JERSEY, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company, and Novocure (NASDAQ: NVCR), a global oncology company working to extend survival in some of the most aggressive forms of cancer, today announced that the final patient has been enrolled in a Novocure-sponsored phase 2 pilot trial conducted by Zai Lab evaluating the safety and efficacy of Tumor Treating Fields (TTFields) in combination with chemotherapy as a first-line treatment in patients with gastric adenocarcinoma. Final data collection is expected in the first half of 2022.

Key Points: 
  • This trial, conducted entirely in China, showcases Zais capabilities as we partner with Novocure to expand treatment options for gastric cancer patients in China.
  • The phase 2 pilot gastric cancer trial of TTFields has enrolled approximately 30 patients in Greater China.
  • We look forward to seeing results from this phase 2 pilot trial with our partner, Zai Lab, and to further exploring the potential of Tumor Treating Fields as a treatment for gastric cancer.
  • Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China

Retrieved on: 
Monday, October 4, 2021
Oncology, Health, Clinical Trials, General Health, Radiology, Biotechnology, Mortality, Glioblastoma, Clinical trial, Cell death, Microtubule, Oxaliplatin, Degenerative disease, Mitosis, Pancreatic cancer, Risk, Cytoplasm, Annual report, Health, Private Securities Litigation Reform Act, NASDAQ, Overalls, U.S. Securities and Exchange Commission, Cancer, Patient, Neoplasm, XELOX, LinkedIn, Adult, Liver cancer, Stomach, Chromosome, Infection, Toxicity, Twitter, Coronavirus, Alternating electric field therapy, Ovarian cancer, Large-cell lung carcinoma, Cell division, Mesothelioma, Stomach cancer, Fundamental, COVID-19, HIV disease progression rates, Drug development, Survival, Safety, Incidence, Cell, Investment, Forward-looking statement, Capecitabine, Data collection, Skin, Protein, Pharmaceutical industry, Medical imaging, Gastric Cancer, Tumor Treating Fields, Novocure, Zai Lab, GASTRIC CANCER, TUMOR TREATING FIELDS, NOVOCURE, ZAI LAB

This trial, conducted entirely in China, showcases Zais capabilities as we partner with Novocure to expand treatment options for gastric cancer patients in China.

Key Points: 
  • This trial, conducted entirely in China, showcases Zais capabilities as we partner with Novocure to expand treatment options for gastric cancer patients in China.
  • The phase 2 pilot gastric cancer trial of TTFields has enrolled approximately 30 patients in Greater China.
  • We look forward to seeing results from this phase 2 pilot trial with our partner, Zai Lab, and to further exploring the potential of Tumor Treating Fields as a treatment for gastric cancer.
  • Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Novocure Announces Clinical Trial Collaboration with Roche to Evaluate Tumor Treating Fields as Part of a Novel Combination for the First-line Treatment of Metastatic Pancreatic Cancer

Retrieved on: 
Tuesday, September 14, 2021
Research, Medical Devices, FDA, Clinical Trials, Radiology, Health, Other Science, Science, Oncology, Pancreatic cancer, Chromosome, Ovarian cancer, Cell, ROG, Stomach, Private Securities Litigation Reform Act, Liver cancer, Forward-looking statement, Alternating electric field therapy, Fundamental, Protein, Patient, Microtubule, Neoplasm, RECIST, Cytoplasm, Glioblastoma, U.S. Securities and Exchange Commission, LinkedIn, Pancreas, Safety, Survival, Adult, Annual report, RO, NASDAQ, Toxicity, Skin, Large-cell lung carcinoma, COVID-19, Mitosis, Cell death, Twitter, Mesothelioma, Death, Cell division, PDAC, Cancer, PFS, Pharmaceutical industry, Medical imaging, Tumor Treating Fields, Novocure, TUMOR TREATING FIELDS, NOVOCURE

ROG; OTCQX: RHHBY), to develop Tumor Treating Fields (TTFields) together with Roches anti-PD-L1 therapy, atezolizumab, in metastatic pancreatic ductal adenocarcinoma (mPDAC).

Key Points: 
  • ROG; OTCQX: RHHBY), to develop Tumor Treating Fields (TTFields) together with Roches anti-PD-L1 therapy, atezolizumab, in metastatic pancreatic ductal adenocarcinoma (mPDAC).
  • Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and accounts for 85%95% of all solid pancreatic tumors.
  • Tumor Treating Fields, or TTFields, are electric fields that disrupt cancer cell division.
  • Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.